Insider Insights
Singapore’s first global drug is being devel...

In a phase 3 study, Crovalimab was found to be efficacious and well tolerated in people with paroxys...

Read more

Stay in the know, subscribe to our newsletter

Be the first to receive exclusive content on the latest from the pharmaceutical and market access sector.